---
title: "Varegacestat (AL102) in Desmoid tumors: Incidence"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Incidence. Topics: Netherlands: extra-abdominal and abdominal wall aggressive fibromatosis, 1993 to 2013; Netherlands: sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses, 1999 to 2009; Denmark: desmoid tumor patients treated at two sarcoma centers, 2009 to 2018; Finland: historical estimates; 6 further topics. 10 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/incidence"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Incidence

<a id="heading-2.2.1.2.1"></a>

## 2.2.1.2.1 Incidence of Desmoid tumors

<a id="topic-2.2.1.2.1-1"></a>

### Netherlands: extra-abdominal and abdominal wall aggressive fibromatosis, 1993 to 2013

> “In a population-based study in the Netherlands, we evaluated time trends for the incidence and treatment of AF.”
> “A total of 1134 patients were diagnosed with extra-abdominal or abdominal wall AF between January 1993 and December 2013; there were 326 men and 808 women.”
> “The incidence increased from 2.10 to 5.36 per million people per year.”
> “The male–female ratio showed an increasing female predominance, ranging from 68.6 % in 1993–1998 to 73.6 % in 2009–2013.”

Source: [van Broekhoven et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4531142/)

<a id="topic-2.2.1.2.1-2"></a>

### Netherlands: sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses, 1999 to 2009

> “For calculation of incidence rates, person-years from the general matched population were used.”
> “The incidences of sporadic and FAP-related desmoid-type fibromatoses were 3.42 and 2,784 per million person-years, respectively.”

Source: [Nieuwenhuis et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/20830713/)

<a id="topic-2.2.1.2.1-3"></a>

### Denmark: desmoid tumor patients treated at two sarcoma centers, 2009 to 2018

> “Using Danish health registers, we studied DT patients treated at two sarcoma centers between 2009 and 2018.”
> “Of the 179 DT patients identified, 76% were female and the median patient age was 38 years at diagnosis (interquartile range: 31-50).”
> “An average annual incidence of DTs over the study period was 3.2 per 1000,000 individuals with the observed annual incidence of DTs ranging from 2.2 (2011) to 4.3 (2017) per 1000,000 individuals. No notable linear time trend in incidence was observed.”

Source: [Anneberg et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35121405/)

<a id="topic-2.2.1.2.1-4"></a>

### Finland: historical estimates

> “The reference standard on the incidence and epidemiology of AF are Finnish studies by Reitamo et al.”
> “An incidence of 2.4–4.3 per million people was reported in those studies, using three methods of estimation (local, regional, and national).”

Source: [van Broekhoven et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4531142/)

<a id="topic-2.2.1.2.1-5"></a>

### Literature review of incidence estimates

> “The low incidence of DT (estimated 3–5 cases per million person-years) limits disease awareness.”
> “Five European sources [24–28] providing estimates on the incidence of DT were identified in the literature.”
> “Likewise, no epidemiological study of DT in the United States (US) was identified.”
> “The Orphanet Report Series [26] provides an average annual incidence of 3 cases of DT per million person-years in Europe.”
> “No estimates of incidence of DT in children are available in the literature; there is a lack of data on DT in children younger than 11 years old.”
> “Because all the epidemiological data are from European populations, a US population-based study will be necessary to compare incidence estimates between Europe and the US.”

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/)

<a id="topic-2.2.1.2.1-6"></a>

### Guideline estimate of incidence

> “DT is a distinctly rare entity (incidence 5–6 cases per 1 million of the population per annum”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.1.2.1-7"></a>

### Age and sex distribution

> “The epidemiological studies reveal that most DT cases appear in the age range of 20–44 years, with a female predominance, and female cases 2.2–3.9 times the number of male cases”

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/)

> “Onset of DT has been reported from infancy through adulthood, although it occurs most commonly between the ages of 15 and 60 years (with peak incidence between 30–40 years of age) and 2–3 times more frequently in women than men”

Source: [Federman (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9448813/)

<a id="topic-2.2.1.2.1-8"></a>

### Company estimate: U.S. annual incidence, SpringWorks Therapeutics

> “Desmoid tumors typically occur in patients between the ages of 15 and 60 years old and are more commonly diagnosed in the third and fourth decades of life, with a two-to-three times higher prevalence in females. The annual incidence is estimated to be 1,000 to 1,650 new desmoid tumor patients diagnosed each year in the United States.”

Source: [SpringWorks Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1773427/000177342725000010/swtx-20241231.htm)

<a id="topic-2.2.1.2.1-9"></a>

### Company estimate: U.S. annual incidence, Immunome

> “They often strike in young adulthood, with 1,000-1,650 patients diagnosed each year in the United States.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

> “Desmoid tumors often strike in young adulthood, with 1,000-1,650 patients diagnosed each year and 10-11,000 actively managed patients in the US”
> “Bektas et al., Advances in Therapy, 2023”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-2.2.1.2.1-10"></a>

### U.S. annual incidence, published estimate

> “These are rare or orphan cancers with an annual incidence of 1000 patients in the United States.”
> “The disease predominantly affects young adults and can arise in any anatomic location but favors the extremities, joints, and abdomen.”

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
